Pacira Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pacira (US): 2 reconciled FDA prescription therapies, $6.3M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$6.3M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$4.3M
California HCAI SB 17 Filings6 WAC filings (max 21.4% 2-yr change)